2025-12-06 - Analysis Report
Okay, here's a breakdown of the provided information and a comprehensive analysis of TransMedics Group Inc. (TMDX).

**1. Return Rate Comparison (TMDX vs. VOO)**

*   **Company Overview:** TransMedics Group Inc is a medical technology company focused on developing and delivering innovative organ care system platforms for end-stage organ failure.
*   **TMDX Cumulative Return:** 244.80%
*   **VOO Cumulative Return:** 76.52%
*   **Divergence:**
    *   Absolute Divergence: 168.28% (244.80% - 76.52%)
    *   Divergence (max: 247.2, min: -74.5, current: 186.2, relative divergence: 81.0)

*   **Analysis:** TMDX has significantly outperformed the S&P 500 (VOO) over the period examined. The absolute divergence of 168.28% means that TMDX has provided 168.28% more return than S&P 500. The *relative divergence* of 81.0% suggests that TMDX's current outperformance is located at the top 81% percentile of past data.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha   | Beta  | Cap(B) |
|------------|---------|-------|---------|-------|--------|
| 2019-2021  | -18.0%  | 83.5% | -61.0%  | -0.0  | 0.6    |
| 2020-2022  | 94.0%   | 83.5% | 95.0%   | 0.0   | 2.1    |
| 2021-2023  | 65.0%   | 80.5% | 64.0%   | 0.1   | 2.6    |
| 2022-2024  | 130.0%  | 85.5% | 109.0%  | 0.1   | 2.1    |
| 2023-2025  | 166.0%  | 85.5% | 100.0%  | 0.3   | 4.7    |

*   **CAGR (Compound Annual Growth Rate):** Shows the average annual growth rate over the period. CAGR has improved over time indicating the increasing value of the company.
*   **MDD (Maximum Drawdown):** Indicates the largest peak-to-trough decline during the period. MDD is high, showing the stock is relatively risky.
*   **Alpha:** Measures the investment's performance on a risk-adjusted basis. High Alpha means the investment is better than the benchmark.
*   **Beta:** Measures the volatility of a stock compared to the overall market. Beta around 0 means TMDX is not correlated to the market. The increase in recent year beta shows the market correlation.
*   **Cap(B):** Market capitalization in Billions. Has increased overall.

**2. Recent Stock Price Fluctuations:**

*   **Current Close:** 140.10
*   **Last Market Data:** Price: 136.92, Previous Close: 138.63, Change: -1.23
*   **5-day SMA:** 143.71
*   **20-day SMA:** 129.32
*   **60-day SMA:** 122.55

*   **Analysis:** The current price (136.92) is below the 5-day SMA (143.71) but above the 20-day (129.32) and 60-day (122.55) SMAs. This suggests that while there may be some short-term downward pressure (price decreased -1.23) , the stock is still trending upward over the medium and long term.

**3. RSI, PPO, and Expected Return Analysis:**

*   **MRI (Market Risk Indicator):** 0.8 (Medium Investment Recommended)
*   **RSI:** 66.17
*   **PPO:** 1.14
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (7 shares - Very Safe - MRI:0.90) Monthly invest 1.2% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent Relative Divergence Change:** 14.5 (+): 단기상승 (Short-term increase)
*   **Expected Return:** 30.0% (Expected excess return compared to S&P 500 if invested long-term)

*   **Analysis:**
    *   The MRI of 0.8 suggests a "Medium Investment Recommended" risk profile.
    *   The RSI of 66.17 is approaching the overbought territory (typically above 70), but not there yet.
    *   The PPO of 1.14 indicates that the 20-day moving average is slightly above the 60-day moving average, supporting the upward trend indicated by the SMAs.
    *   The Hybrid Signal suggest a strong buy signal, which can also be attributed to the 30.0% expected return.

**4. Recent News & Significant Events:**

*   **Key Headlines:**
    *   Brown Capital Management LLC Sells Shares
    *   Valuation Evaluation After Share Price Gains
    *   Earnings Beat Estimates
    *   Fireside Chat at Piper Sandler Conference
    *   Morgan Stanley Raises Price Target
    *   CEO’s Stock Purchase Signals Confidence
*   **Analysis:** The news presents a mixed picture.
    *   **Positive Signals:** Morgan Stanley raising the price target and the CEO's stock purchase indicate confidence in the company's future. The earnings beat estimates also suggests strong financial performance.
    *   **Neutral to Negative Signals:** Brown Capital Management selling shares could be interpreted as a lack of confidence, but could also be due to portfolio rebalancing. The article evaluating valuation after share price gains suggests a need to examine whether the stock is overvalued.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy (Mean: 1.67)
*   **Target Price:**
    *   Average: $143.00
    *   High: $170.00
    *   Low: $114.00

*   **Analysis:** Analyst consensus is "Buy" with a mean rating of 1.67. The average target price of $143.00 is slightly above the current price of $136.92, suggesting further upside potential.

**5. Comprehensive Analysis:**

TransMedics Group Inc. (TMDX) has demonstrated significant outperformance compared to the S&P 500 (VOO). The company's financial performance appears strong, as indicated by its earnings beat, analyst ratings, positive alpha values, high CAGR and the CEO's stock purchase.

**Key takeaways:**

*   **Growth Stock:** TMDX appears to be a high-growth stock with substantial potential, particularly in the long term. The expected 30% excess return and analysts' high target price further support this.
*   **Risk:** The MDD and beta values also highlight the volatile nature of the stock.
*   **Valuation:** Be aware of the potential for overvaluation, as suggested by one of the news articles.

**Recommendation:**

Based on the analysis, TMDX appears to be a good investment opportunity for those seeking high growth potential and willing to tolerate higher risk. The Buy consensus from analysts and high expected return are promising. However, due diligence is recommended to carefully evaluate the current valuation and understand the factors driving the company's growth.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.